NVCR · NASDAQ
NovoCure (NVCR) Stock Price & Fundamentals
NovoCure (NVCR) closed at $711.35 on Oct 9, 2026, down 0.71% from the previous close of $716.43.
Share price, past year
1Y +11.04%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $711.35 |
| Sep 30, 2026 | $727.53 |
| Aug 31, 2026 | $736.93 |
| Jul 31, 2026 | $726.37 |
| Jun 30, 2026 | $721.71 |
| May 29, 2026 | $670.63 |
| Apr 30, 2026 | $694.66 |
| Mar 31, 2026 | $689.71 |
| Feb 27, 2026 | $646.95 |
| Jan 30, 2026 | $677.29 |
| Dec 31, 2025 | $663.89 |
| Nov 28, 2025 | $653.84 |
| Oct 31, 2025 | $656.03 |
Key statistics
- Market cap
- $82.83B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.30
- Revenue (TTM)
- $699.19M
- Net income (TTM)
- −$148.57M
- Shares outstanding
- 116.4M
- Dividend yield
- —
- 52-week range
- $634.42 – $760.27
NovoCure's market cap is $82.83B, based on a share price of $711.35 and 116.4M shares outstanding as of Jun 30, 2026.
Financials
NovoCure reported revenue of $655.35M for fiscal 2025, up 8.28% from fiscal 2024.
NovoCure reported a net loss of $136.23M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $655.35M | +8.3% | −$136.23M | −20.8% | −$1.22 | −$75.68M |
| FY2024ended Dec 31, 2024 | $605.22M | +18.8% | −$168.63M | −27.9% | −$1.56 | −$69.22M |
| FY2023ended Dec 31, 2023 | $509.34M | −5.3% | −$207.04M | −40.7% | −$1.95 | −$100.43M |
| FY2022ended Dec 31, 2022 | $537.84M | +0.5% | −$92.53M | −17.2% | −$0.88 | $9.43M |
| FY2021ended Dec 31, 2021 | $535.03M | +8.2% | −$58.35M | −10.9% | −$0.56 | $58.59M |
| FY2020ended Dec 31, 2020 | $494.37M | +40.7% | $19.81M | 4.0% | $0.18 | $84.18M |
| FY2019ended Dec 31, 2019 | $351.32M | +41.6% | −$7.23M | −2.1% | −$0.07 | $16.14M |
| FY2018ended Dec 31, 2018 | $248.07M | +40.1% | −$63.56M | −25.6% | −$0.69 | −$8.58M |
| FY2017ended Dec 31, 2017 | $177.03M | +113.6% | −$61.66M | −34.8% | −$0.70 | −$40.50M |
| FY2016ended Dec 31, 2016 | $82.89M | — | −$131.85M | −159.1% | −$1.54 | −$113.27M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $183.58M | −$15.66M | −$0.13 |
| Q1 FY2026ended Mar 31, 2026 | $174.06M | −$71.14M | −$0.62 |
| Q4 FY2025ended Dec 31, 2025 | $174.35M | −$24.50M | −$0.22 |
| Q3 FY2025ended Sep 30, 2025 | $167.20M | −$37.27M | −$0.33 |
| Q2 FY2025ended Jun 30, 2025 | $158.81M | −$40.14M | −$0.36 |
| Q1 FY2025ended Mar 31, 2025 | $154.99M | −$34.32M | −$0.31 |
| Q4 FY2024ended Dec 31, 2024 | $161.27M | −$65.92M | −$0.61 |
| Q3 FY2024ended Sep 30, 2024 | $155.10M | −$30.57M | −$0.28 |
Company profile
- Name
- NovoCure Ltd
- Ticker
- NVCR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Surgical & Medical Instruments & Apparatus
- Headquarters
- No. 4 The Forum, Grenville Street, St. Helier
- Fiscal year ends
- December
- SEC CIK
- 0001645113
Recent SEC filings
- Oct 1, 2026
- Sep 9, 2026
- Sep 1, 2026
- Jul 23, 2026
- Jul 23, 2026
- Jun 30, 2026
- Jun 18, 2026
- Jun 5, 2026
Frequently asked questions
What is NovoCure's stock price?
NovoCure (NVCR) closed at $711.35 on Oct 9, 2026, down 0.71% from the previous close of $716.43.
What is NovoCure's market cap?
NovoCure's market cap is $82.83B, based on a share price of $711.35 and 116.4M shares outstanding as of Jun 30, 2026.
How much revenue does NovoCure make?
NovoCure reported revenue of $655.35M for fiscal 2025, up 8.28% from fiscal 2024.
Does NovoCure pay a dividend?
NovoCure's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from NovoCure Ltd's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures